Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers

Tenax Therapeutics’ Phase 3 LEVEL trial of TNX-103 failed to meet its primary endpoint and key secondary endpoint, according to the company’s August 10, 2026 release; its shares fell about $12.06, or 89.77%, to approximately $1.38 that day. A securities class action alleges Tenax and certain officers overstated the drug’s effectiveness and clinical, regulatory, and commercial prospects; these are allegations, not established findings. Investors who acquired Tenax securities from November 13, 2023, through August 7, 2026, have until December 28, 2026, to seek appointment as lead plaintiff.

Analysis

The lawsuit announcement is not a new read-through on levosimendan efficacy: the decisive fundamental repricing followed the Phase 3 failure. The incremental effect is a legal and governance overhang, not a fresh clinical catalyst. Filing a complaint does not establish liability, and the lead-plaintiff deadline is procedural; absent new allegations or evidence, it is unlikely to restore the lost product value or independently justify a large repricing.

For TENX, the key residual valuation question is now balance-sheet runway and the value of any remaining pipeline or corporate alternatives—not the former LEVEL thesis. Litigation could consume management attention and add costs, but the size and timing of any ultimate liability are unknown. The more material tail risk is that investors extrapolate a failed lead asset into limited financing options or a distressed strategic outcome; the converse is a cash-rich balance sheet or credible alternative program that is not described here.

Near term, expect volatility and possible liquidity-driven moves around further disclosures, rather than a reliable legal-case signal. Over 1–3 months, monitor cash, burn, any restructuring or strategic review, and the complaint’s specific factual allegations. Over 6–18 months, asset disposition, pipeline reprioritization, or financing terms would matter more than the class-action calendar. Contrarian point: the lawsuit headline sounds newly bearish, but much of the core clinical damage is already public; shorting solely on this release risks chasing a collapsed stock into a cash/optionality rebound. No price target is supportable from the supplied data.

Key Decisions for Investors

• Do not initiate a short solely on the lawsuit notice. The clinical failure is known and the filing is an allegation; avoid a fresh position until current price, liquidity, borrow availability, and balance-sheet data are checked.
• Keep TENX on an event-driven watchlist. Verify latest cash and equivalents, quarterly burn, debt or other obligations, remaining pipeline/IP, and share count before assigning value to residual assets or assessing financing risk.
• Treat new company disclosures as the principal catalysts: reassess on a cash-runway update, restructuring or strategic transaction, financing, or material pipeline decision. A sharp deterioration in runway or highly dilutive financing would falsify the residual-optionality case.
• Track the complaint for specific, previously undisclosed facts and any material insurance, indemnification, or governance developments; do not equate the filing or lead-plaintiff deadline with a finding of fraud or a near-term cash liability.